, with a confirmed diagnosis on admission International classification of diseases (ICD-X: J18.
9AL-QUFAISH, M.A.M.,
USMANOVA, I.N.,
TUIGUNOV, M.M.,
KHUSNARIZANOVA, R.F.,
GUMEROVA, M.I.,
SHANGAREEVA, A.I. (2021) on an intact periodontium (71.1%) and reduced periodontium (22.
9%). Periodontal pathogens as a risk factor were
Shnayder, N.A.,
Novitsky, M.A.,
Neznanov, N.G.,
Limankin, O.V.,
Asadullin, A.R.,
Petrov, A.V.,
Dmitrenko, D.V.,
Narodova, E.A.,
Popenko, N.V.,
Nasyrova, R.F. (2022) , CACNB2, and BCL
9. Conclusion: Planning and conducting genome-wide and associative genetic studies
and analyzed: 25 focused on lncRNAs-based therapeutics and
9 on lncRNAs-based diagnosis. We found 31 different
Lin, Jianjun,
Lin, Ke,
Huang, Lijiang,
Jiang, Yongsheng,
Ding, Xiaoxiao,
Luo, Wu,
Samorodov, Aleksandr V.,
Pavlov, Valentin N.,
Liang, Guang,
Qian, Jianchang,
Wang, Yi (2022) -/- mice. Furthermore, pharmacological inhibition of MD2 by L6H
9 ameliorates heme-induced inflammation
Idrisov, Bulat,
Lunze, Karsten,
Cheng, Debbie M.,
Blokhina, Elena,
Gnatienko, Natalia,
Patts, Gregory,
Bridden, Carly,
Rossi, Sarah L.,
Weiser, Sheri D.,
Krupitsky, Evgeny,
Samet, Jeffrey H. (2023) in the past 90 days was 13.4 (SD 30.1);
9.7% reported sharing needles/syringes in the past month. We did
Timasheva, Y.,
Balkhiyarova, Z.,
Avzaletdinova, D.,
Rassoleeva, I.,
Morugova, T.V.,
Korytina, G.,
Prokopenko, I.,
Kochetova, O. (2023) = 1.77, PFDR =
9.37 × 10−5), and CCL2 rs1024611 (OR = 1.38, PFDR = 0.033) polymorphisms. We showed